-+ 0.00%
-+ 0.00%
-+ 0.00%

UniQure's US-listed stock fell 68% in the premarket after the company revealed that its early-to mid-term research on gene therapy for Huntington's disease fell short of expectations.

Zhitongcaijing·09/29/2026 11:25:10
Listen to the news
UniQure's US-listed stock fell 68% in the premarket after the company revealed that its early-to mid-term research on gene therapy for Huntington's disease fell short of expectations.